Activated VEGFR2/KDR Pathway in Tumour Cells and Tumour Associated Vessels of Colorectal Cancer
Overview
Authors
Affiliations
Background: Vascular endothelial cell growth factor (VEGF) acts by phosphorylating specific tyrosine kinase receptors on endothelial cell membrane promoting angiogenesis. The study of the activation status of VEGF receptors in human malignancies has recently become feasible by means of specific monoclonal antibodies recognising the phosphorylated form of these receptors.
Materials And Methods: In the current study, we investigate the expression of the phosphorylated VEGFR2/KDR receptor in normal colon and colorectal adenocarcinomas in parallel with histopathological parameters, prognosis and the expression of the 'hypoxia inducible factor' HIF1alpha.
Results: pVEGFR2/KDR was weakly expressed in the normal colon, but it was expressed strongly in the cytoplasm and nuclei of cancer cells and in the tumour associated vasculature, mainly at the invading tumour edge. pVEGFR2/KDR expression in cancer cells was significantly associated with a tumour diameter > 6 cm (P = 0.04), poor histological differentiation (P = 0.004) and with high CEF1alpha expression (P = 0.05). High pVEGFR2/KDR expressing vascular density was significantly related with a high VEGF and HIF1alpha expression in cancer cells (P = 0.02 and 0.03, respectively). This was also related significantly to high pVEGFR2/KDR expression in cancer cells. In multivariate analysis, the most significant predictors for death were lympho-vascular invasion (P < 0.001) followed by VEGF (P = 0.014), node status (P = 0.015), standard vascular density (P = 0.022) and necrosis (P = 0.032).
Conclusions: pVEGFR2 receptors are largely expressed in colon cancer cells and intratumoural vasculature. As VEGF targeting agents enter the clinical practice, the role of monoclonal antibodies recognising the phosphorylated form of VEGF receptors as predictors of response to targeted therapies should be sought in clinicopathological trials.
A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic.
Beig Parikhani A, Dehghan R, Talebkhan Y, Bayat E, Biglari A, Shokrgozar M AMB Express. 2024; 14(1):19.
PMID: 38337114 PMC: 10857990. DOI: 10.1186/s13568-023-01648-2.
Huang Z, Zhu W, Wang C, Mo L, Huang H, Tong X Evid Based Complement Alternat Med. 2023; 2023:8808422.
PMID: 37114147 PMC: 10129418. DOI: 10.1155/2023/8808422.
Hitrec T, Petit C, Cryer E, Muir C, Tal N, Fustin J iScience. 2023; 26(2):106002.
PMID: 36866044 PMC: 9971895. DOI: 10.1016/j.isci.2023.106002.
Cao Y, Sun C, Huo G, Wang H, Wu Y, Wang F Cancer Sci. 2022; 114(1):115-128.
PMID: 36114822 PMC: 9807522. DOI: 10.1111/cas.15594.
Association of the VEGFR2 single nucleotide polymorphism rs2305948 with glioma risk.
Sun S, Li X, Qu B, Xie K, Li J, Miao J Medicine (Baltimore). 2022; 101(1):e28454.
PMID: 35029892 PMC: 8735747. DOI: 10.1097/MD.0000000000028454.